Nothing Special   »   [go: up one dir, main page]
Scribd Logo
Upload

Welcome to Scribd!

  • 101 views

    COVID 19 Vaccine Comparison Chart

    Uploaded by

    Nuklear Adiwena
    This document compares key details of 5 major COVID-19 vaccines: Pfizer/BioNTech, Moderna, J&J, AstraZeneca, and Novavax. It summarizes each vaccine's name, type, approved age, dosage, efficacy including against variants, and references clinical trial results. The vaccines show efficacy rates ranging from 66-95% and protect against severe disease and death. Ongoing research is evaluating booster doses and variant-specific vaccines.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    COVID 19 Vaccine Comparison Chart

    Uploaded by

    Nuklear Adiwena
    101 views2 pages
    This document compares key details of 5 major COVID-19 vaccines: Pfizer/BioNTech, Moderna, J&J, AstraZeneca, and Novavax. It summarizes each vaccine's name, type, approved age, dosage, efficacy including against variants, and references clinical trial results. The vaccines show efficacy rates ranging from 66-95% and protect against severe disease and death. Ongoing research is evaluating booster doses and variant-specific vaccines.

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document compares key details of 5 major COVID-19 vaccines: Pfizer/BioNTech, Moderna, J&J, AstraZeneca, and Novavax. It summarizes each vaccine's name, type, approved age, dosage, efficacy including against variants, and references clinical trial results. The vaccines show efficacy rates ranging from 66-95% and protect against severe disease and death. Ongoing research is evaluating booster doses and variant-specific vaccines.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    101 views2 pages

    COVID 19 Vaccine Comparison Chart

    Uploaded by

    Nuklear Adiwena
    This document compares key details of 5 major COVID-19 vaccines: Pfizer/BioNTech, Moderna, J&J, AstraZeneca, and Novavax. It summarizes each vaccine's name, type, approved age, dosage, efficacy including against variants, and references clinical trial results. The vaccines show efficacy rates ranging from 66-95% and protect against severe disease and death. Ongoing research is evaluating booster doses and variant-specific vaccines.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 2

    COVID-19 VACCINE COMPARISON CHART

    Pfizer/BioNTech Moderna J&J (Janssen) AstraZeneca Novavax


    Name BNT162b2 mRNA-1273 Ad26.COV2.S ChAdOx1 nCoV-19 NVX-CoV2372
    Vaccine Type mRNA mRNA Adenovirus vector Adenovirus vector Recombinant
    nanoparticle
    Age ≥ 16 years old ≥ 18 years old ≥ 18 years old ≥ 18 years old ≥ 18 years old
    Dosage 2 doses (0.3 mL) 2 doses (0.5 mL) 1 dose (0.5 mL) 2 doses 2 doses
    21 days apart 28 days apart 4-12 weeks apart 21 days apart

    EFFICACY

    Overall - 95% (7 days after 2nd - 94.1% (14 days -66.1% (overall)3.4 - 66.7% (overall; >14 -89.7% (overall ; 7 days
    dose) after 2nd dose)2 -72.0% (US)3.4 days after 2nd after 2nd dose)6
    - 90% (for mRNA - 90% (for mRNA dose)5
    vaccines under real- vaccines under real- -82.4% (2nd dose
    world conditions; ≥14 world conditions; ≥12 wks after 1st
    days after 2nd dose)14 ≥14 days after 2nd dose)5
    dose)14 -54.9% (2nd dose <6
    wks after 1st dose)5
    -76% (US overall; 15
    days after 2nddose)13
    In Elderly Persons 94.7% (≥65 years)1 86.4% (≥65 years)2 66.2% (≥60 years)4 Limited data 27% of patients were ≥ 65
    years6
    In Adolescents 100%15 n/a n/a n/a n/a
    (12-15 years old)
    In Severe Disease 90%1 100%2 Overall: 85.4%4 100%5,8 100%9
    US: 87.6%4
    COVID-19 Death 100%1 100%2 100%4 100% 100%9
    UK Variant (B.1.1.7) In vitro activity10 In vitro activity11 ≈ 60-75%7 74.6%5 86.3%9
    South Africa Variant In vitro lower In vitro lower 64.0%4 10.4%12 48.69
    (B1.351) activity10 activity11
    Brazil Variant (P.1) In vitro activity10 In vitro lower 68.1%4 Effective (prelim Data not available
    activity11 data)
    Variant – Specific Developing booster Developing booster Adapting vaccine Adapting vaccine Developing booster
    Vaccine
    COVID-19 VACCINE COMPARISON CHART

    REFERENCE LIST

    1. FP Polack et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603.
    2. LR Baden et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403.
    3. News Release. Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3
    ENSEMBLE trial. Available at: https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-
    interim-analysis-of-its-phase-3- ensemble-trial. Accessed March 19, 2021.
    4. FDA. Fact sheet for healthcare providers administering vaccine. Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent Coronavirus
    Disease 2019 (COVID-19). Available at: https://www.fda.gov/media/146304/download?utm_medium=email&utm_source=govdelivery. Accessed March 19,
    2021.
    5. M Voysey et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV19
    (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397:881.
    6. News Release. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial. Available at: https://ir.novavax.com/news-releases/news-
    releasedetails/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Accessed March 19, 2021.
    7. J Lopez Bernal et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic
    disease, hospitalisations and mortality in older adults in England. medRxiv 2021 March 2 (epub). Available at:
    https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1. Accessed March 19, 2021.
    8. M Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in
    Brazil, South Africa, and the UK. Lancet 2021; 397:99.
    9. News Release. Novavax confirms high levels of efficacy against original and variant COVID-19 strains in United Kingdom and South Africa trials. 2021 March 11
    Available at: https://www.prnewswire.com/news-releases/novavax-confirms-high-levels-of-efficacy-against-original-and-variant-covid-19-strains-in-united-
    kingdom-and-south-africatrials-301246019.html. Accessed March 19, 2021.
    10. Y Liu et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med 2021 March 8 (epub).
    11. K Wu et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med 2021 March 17 (epub).
    12. SA Madhi et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021 March 16 (epub).
    13. News Release. AZD1222 US Phase III primary analysis confirms safety and efficacy. 2021 March 25. Available at:
    https://www.astrazeneca.com/content/astraz/mediacentre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html.
    Accessed March 26,2021.
    14. MG Thompson et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among
    health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly
    Rep 2021 March 29 (epub).
    15. News Release. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents. March 31, 2021. Available at:
    https://investors.biontech.de/news-releases/news-release-details/pfizer-biontech-announce-positive-topline-results-pivotal-covid/. Accessed March 31, 2021.

    You might also like